References
- Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353–60
- Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 1998;12:335–44
- Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey [The Fatigue Coalition]. Semin Hematol 1997;34:4–12
- Anderson ER, Gibson G. Considerations in darbepoetin alfa cost and reimbursement: a model for pharmacy managers. Pharmacotherapy 2003;23:119S–124S
- Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Cur Med Res Opin 2004;20:381–95
- Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures – 2005. Am J Health-Syst Pharm 2005;62:149–67
- Ortho Biotech Products, L.P. Procrit* (epoetin alfa) package insert. Raritan (NJ); 2005
- Amgen, Inc. Aranesp* (darbepoetin alfa) package insert. Thousand Oaks (CA); 2002
- Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–20
- Kotasek D, Canon J-L, San Miguel J, et al. Correction/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized phase 3 active controlled trial [poster presentation]. American Society of Hematology, December 4–7, 2004, San Diego, California
- Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 200520;23: 2606–17
- Cremieux PY, Greenberg P, Piech CT. Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia. Proc Am Soc Clin Oncol 2003;22:559
- Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82
- List price for Procrit and for Aranesp from May 2005 Medi-Span Master Drug Data Base (MDDB).
- Gold MR, Siegel E, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
- Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998;7:723–40
- Centers for Medicare & Medicaid Services. April 2005 ASP Pricing File and ASP NOC Pricing File [online]. Available from https://www.cms.hhs.gov/providers/drugs/asp.asp [last accessed 28 April 2005]
- Ben-Hamadi R, Duh M, Henckler A, et al. Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy- induced anemia. Proc Am Soc Clin Oncol 2005;23:551
- Ben-Hamadi R, Duh MS, Aggarwal J, et al. Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy-induced anemia [presentation]. International Society for Pharmacoeconomics and Outcomes Research, May 15–18, 2005, Washington, DC
- Cremieux PY, Fastenau JM, Kosicki G, et al. Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. J Manag Care Pharm 2004;10:531–7
- Waltzman R, Croot C, Justice G, et al. Randomized comparison of epoetin alfa 40 000U QW and darbepoetin alfa 200 μg Q2W in anemic patients with cancer receiving chemotherapy. Oncologist [in press]